We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Results from a Chinese trial of Gilead’s antiviral remdesivir show no benefit in COVID-19 patients, according to data accidentally posted on the World Health Organization’s (WHO) website. Read More
With dozens of clinical trials of hydroxychloroquine as a COVID-19 treatment currently in the planning or enrollment stages, there are mounting concerns that the drug’s risks could outweigh the benefits for COVID-19 patients. Read More
The FDA’s Coronavirus Treatment Acceleration Program is gearing up for a second wave of potential COVID-19 treatments and vaccines as the search for effective products gains momentum. Read More
Alexion Pharmaceuticals plans to initiate a global phase 3 clinical trial to evaluate Ultomiris (ravulizumab-cwvz) in hospitalized patients with severe COVID-19. Read More
Novartis said it will begin enrollment in the next few weeks for a phase 3 clinical trial to evaluate hydroxychloroquine for treatment of hospitalized COVID-19 patients. The trial will include more than 440 participants at more than a dozen U.S. sites. Read More